Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (102396)	6/14/2000 5:32:00 PM
From: kha vu	Read Replies (1) \| Respond to of 120523

MRVC: after hour 54 1/4. Thanks for your analysis on MRVC. When the correction in April ran wild on the portfolio, I decided to hold/add MRVC. Now it is really payoff. As for this market, it is a psycho market. CPI is out now, but it does not help at all. Maybe we need another THREE day weekend to move this market.

To: Jenna who wrote (102396)	6/14/2000 7:07:00 PM
From: nokomis	Respond to of 120523

To: Jenna who wrote (102396)	6/15/2000 1:04:00 PM
From: lizard lick	Read Replies (1) \| Respond to of 120523

Buying CVM today for a hold,, DJN: DJ Cel-Sci/Cancer Institute -2: Seeks To Develop HIV Vaccine (Dow Jones 06/15 12:45:10) VIENNA, Va. (Dow Jones)--Cel-Sci Corp. (CVM) and the National Cancer Institute agreed to jointly test the institute's HIV peptide epitopes and the company's L.E.A.P.S. platform technology for peptide delivery. In a press release Thursday, Cel-Sci said the collaboration seeks to develop an improved HIV vaccine for use in HIV treatment and prevention. The collaboration will evaluate the types of immune responses elicited by L.E.A.P.S. constructs using HIV peptides developed in specialized animal testing models available at the Institute. The L.E.A.P.S. technology allows for the preparation of designer vaccines that can selectively target particular immune cells and elicit cellular or humoral (antibody) responses. Cel-Sci's American Stock Exchange-listed shares recently traded at 3 1/4, up 3/16 or 6.1%, on composite volume of 32,800 shares, compared with average daily volume of 174,101 shares. -Dorothea Degen; Dow Jones Newswires; 201-938-5400 (END) DOW JONES NEWS 06-15-00 12:45 PM S.DJ CVM I/BTC I/MTC N/DJN N/DJWI M/NND M/TEC P/DPH R/NME R/US R/USS R/VA